Banarian Nordic Res (BVNKF) 55.8000 $BVNKF
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 6.13 (+0.25), BIIB: 425.65 (-0.98), NWBO: 8.30 (-0.14), ADXS: 19.73 (+0.86), ADRO: (), AMGN: 163.38 (+1.89), GSK: 48.23 (+0.51), ONTY: 1.70 (+0.02), IMUC: 0.44 (unch), MACK: 12.17 (+0.17), GBIM: 9.53 (+0.50), ARGS: 8.82 (-0.02), BLCM: 24.88 (+0.68), NLNK: 55.38 (-0.33)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.81 (unch), NBS: 2.98 (+0.06), OSIR: 17.56 (+0.84), BCLI: 4.63 (+0.31), MDVN: 132.44 (+0.38), INO: 9.78 (-0.18), CYTX: 1.24 (-0.02), STEM: 1.00 (-0.01), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07), BLUE: 126.34 (+1.49), VRTX: 128.47 (+2.83), AMGN: 163.38 (+1.89), KERX: 12.42 (+0.09), OMER: 24.58 (+0.44), KITE: 58.34 (+0.22), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77)
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Fri Mar 27, 3:26AM CDT
KVISTGAARD, Denmark, March 27, 2015 - Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the annual General Meeting to be held on
Bavarian Nordic A/S - Major Shareholder Announcement
Thomson Reuters ONE - Fri Mar 13, 4:36PM CDT
KVISTGAARD, Denmark, March 13, 2015 - Pursuant to Section 29 of the Danish Securities Trading Act it is hereby announced, that ATP has decreased its ownership in Bavarian Nordic and now holds 2,741,918 shares in Bavarian Nordic corresponding to 9.91 % of the share capital and voting rights in Bavarian Nordic.
Bavarian Nordic Announces 2014 Full Year Results
Thomson Reuters ONE - Wed Mar 11, 1:38AM CDT
KVISTGAARD, Denmark, March 11, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today published its 2014 annual report. Revenue was DKK 1,217 million / USD 175 million (DKK 1,213 million / USD 175 million in 2013). The Group recorded an EBIT of DKK 17 million / USD 2 million (DKK 33 million / USD 5 million in 2013) and a net profit of DKK 26 million / USD 4 million (DKK 47 million loss / USD 7 million loss). Revenue and results were in line with the expectations for the year. At year-end 2014, the cash preparedness was DKK 1,000 million / USD 144 million (DKK 652 million / USD 94 million as of 31 December 2013).
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
PR Newswire - Fri Jan 16, 5:29AM CST
Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than EUR 100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
JNJ: 102.06 (+0.73)
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN(R) Filo and Janssen's AdVac(R) technology
Thomson Reuters ONE - Tue Jan 06, 1:00AM CST
- First human trial of the MVA-BN(R) Filo/AdVac(R) preventative Ebola vaccine regimen initiated in the UK
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
PR Newswire - Tue Jan 06, 1:00AM CST
Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
JNJ: 102.06 (+0.73)
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer
GlobeNewswire - Wed Dec 10, 12:41AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC(R), in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.
Bavarian Nordic Announces First Subject Dosed with MVA-BN(R) Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines
Thomson Reuters ONE - Thu Dec 04, 12:31AM CST
- First human trial investigating MVA-BN(R) Filo as an Ebola vaccine
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants
Thomson Reuters ONE - Tue Nov 18, 3:21AM CST
KVISTGAARD, Denmark, November 18, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 1,217,500 as a consequence of the exercise of warrants. After registration of the capital increase, Bavarian Nordic A/S' share capital amounts to DKK 275,665,970.
Bavarian Nordic Announces Interim Results for the First Nine Months of 2014
Thomson Reuters ONE - Thu Nov 13, 12:42AM CST
KVISTGAARD, Denmark, November 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2014.
Bavarian Nordic to Host Third Quarter 2014 Results Conference Call
Thomson Reuters ONE - Thu Nov 06, 10:30AM CST
KVISTGAARD, Denmark - November 6, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2014 third quarter results on Thursday, November 13, 2014.
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 29, 4:15AM CDT
Summary: Bavarian Nordic increases its share capital by nominally DKK 13,319,840 (1,331,984 new shares of DKK 10 each) as a result of a direct placement to Johnson & Johnson Development Corporation ("JJDC"
in connection with the license and supply agreement for the Company's MVA-BN(R) vector in respect of Ebola with Crucell Holland B.V., one of the Janssen Pharmaceutical companies of Johnson & Johnson.
JNJ: 102.06 (+0.73)
Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN(R) for Additional Infectious Disease Targets
Thomson Reuters ONE - Wed Oct 22, 4:47PM CDT
KVISTGAARD, Denmark, October 22, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to expand the collaboration announced earlier today to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets.
JNJ: 102.06 (+0.73)
Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
GlobeNewswire - Wed Oct 22, 1:06AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today a global license and supply agreement for its MVA-BN Filovirus (Ebola and Marburg) vaccine candidate with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
JNJ: 102.06 (+0.73)
Bavarian Nordic Announces Additional Details Concerning the Issue of Shares to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 22, 12:56AM CDT
Summary: Further details on the placement of Bavarian Nordic shares to Johnson & Johnson Development Corporation ("J&J" in connection with an agreement for co-development and commercialization of the Company's MVA-BN(R) vector in respect of Ebola. J&J will subscribe for Bavarian Nordic shares in the amount of DKK 251,000,000. However, Bavarian Nordic will issue a maximum of 1,673,333 shares of DKK 10 each (equal to approximately 6.4 per cent of the existing share capital of the Company). The number of subscribed shares may be lower than 1,673,333 shares depending on the final subscription price. The new shares will be subscribed for in cash at the market price which is based on the simple average of the volume weighted average price of the Company's shares on Nasdaq Copenhagen ("Nasdaq" (Bloomberg VWAP for BAVA.DC, referred to as "VWAP" during a period of five consecutive trading days starting on 22 October 2014, subject to a minimum subscription price of DKK 150 per share of DKK 10 corresponding to the closing price of the Company's shares on Nasdaq on 21 October 2014.
JNJ: 102.06 (+0.73)
Global & USA Cancer Immunotherapy Market Analysis 2015-2020
M2 - Fri Apr 10, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z6tkxf/global_and_usa) has announced the addition of the "GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors" report to their offering. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion. Any drug that can provide a reasonable survival of more than five years for the cancer patients can achieve a blockbuster status. Within the cancer therapeutics, the immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only the cancer cells. Scope - An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies. - Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines. - Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs. - Descriptions about 23 cancer immunotherapeutics approved and used as targeted drugs (some of these products have already been withdrawn from the market). - Insight into the various immunotherapeutics available for specific cancer types. - Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics. - Overall global cancer therapeutics market, leading market players and the bestselling cancer drugs. - Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs. - Profiles, marketed products and products in pipeline of 76 companies that are mostly located in the U.S. and Europe. - Summary table to identify the category of immunotherapy drug offered by the 76 companies. Companies Mentioned - 30 of the 75 Companies Featured - Ablynx NV - Activartis Biotech GmbH - Advaxis Inc. - Aduro BioTech Inc. - Agenus Inc. - AlphaVax Inc. - Amgen Inc. - Antigen Express Inc. - Argos Therapeutics Inc. - Bavarian Nordic A/S - Bellicum Pharmaceuticals Inc. - Biogen Idec Inc.x - Biovest International Inc. - Genmab AS - GlaxoSmithKline - Gliknik Inc. - GlobeImmune Inc. - Heat Biologics Inc. - Immatics Biotechnologies GmbH - ImmunoCellular Therapeutics Ltd. - Merrimack Pharmaceuticals Inc. - Morphotek Inc. - NewLink Genetics Corp. - Northwest Biotherapeutics Inc. - NovaRx Corp. - OncoPep Inc. - Oncothyreon Inc. - OSE Pharma SA - Viventia Biotechnologies Inc. - Wilex AG For more information visit http://www.researchandmarkets.com/research/z6...al_and_usa
HTBX: 6.13 (+0.25), BIIB: 425.65 (-0.98), NWBO: 8.30 (-0.14), ADXS: 19.73 (+0.86), ADRO: (), AMGN: 163.38 (+1.89), GSK: 48.23 (+0.51), ONTY: 1.70 (+0.02), IMUC: 0.44 (unch), MACK: 12.17 (+0.17), GBIM: 9.53 (+0.50), ARGS: 8.82 (-0.02), BLCM: 24.88 (+0.68), NLNK: 55.38 (-0.33)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.81 (unch), NBS: 2.98 (+0.06), OSIR: 17.56 (+0.84), BCLI: 4.63 (+0.31), MDVN: 132.44 (+0.38), INO: 9.78 (-0.18), CYTX: 1.24 (-0.02), STEM: 1.00 (-0.01), JUNO: 60.39 (+1.15), ATHX: 3.03 (+0.03), CUR: 1.94 (+0.07), BLUE: 126.34 (+1.49), VRTX: 128.47 (+2.83), AMGN: 163.38 (+1.89), KERX: 12.42 (+0.09), OMER: 24.58 (+0.44), KITE: 58.34 (+0.22), GILD: 101.77 (+0.61), MRK: 57.25 (-0.18), TEVA: 66.37 (-0.77)
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
Thomson Reuters ONE - Fri Mar 27, 3:26AM CDT
KVISTGAARD, Denmark, March 27, 2015 - Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the annual General Meeting to be held on
Bavarian Nordic A/S - Major Shareholder Announcement
Thomson Reuters ONE - Fri Mar 13, 4:36PM CDT
KVISTGAARD, Denmark, March 13, 2015 - Pursuant to Section 29 of the Danish Securities Trading Act it is hereby announced, that ATP has decreased its ownership in Bavarian Nordic and now holds 2,741,918 shares in Bavarian Nordic corresponding to 9.91 % of the share capital and voting rights in Bavarian Nordic.
Bavarian Nordic Announces 2014 Full Year Results
Thomson Reuters ONE - Wed Mar 11, 1:38AM CDT
KVISTGAARD, Denmark, March 11, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today published its 2014 annual report. Revenue was DKK 1,217 million / USD 175 million (DKK 1,213 million / USD 175 million in 2013). The Group recorded an EBIT of DKK 17 million / USD 2 million (DKK 33 million / USD 5 million in 2013) and a net profit of DKK 26 million / USD 4 million (DKK 47 million loss / USD 7 million loss). Revenue and results were in line with the expectations for the year. At year-end 2014, the cash preparedness was DKK 1,000 million / USD 144 million (DKK 652 million / USD 94 million as of 31 December 2013).
Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative
PR Newswire - Fri Jan 16, 5:29AM CST
Johnson & Johnson (NYSE: JNJ) is pleased to announce the formation of consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical Companies to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than EUR 100 million from the Ebola+ programme to support the development, manufacturing and patient education for the vaccine regimen.
JNJ: 102.06 (+0.73)
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial for the Ebola Vaccine Regimen of MVA-BN(R) Filo and Janssen's AdVac(R) technology
Thomson Reuters ONE - Tue Jan 06, 1:00AM CST
- First human trial of the MVA-BN(R) Filo/AdVac(R) preventative Ebola vaccine regimen initiated in the UK
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
PR Newswire - Tue Jan 06, 1:00AM CST
Johnson & Johnson (NYSE: JNJ) today announced the start of a Phase 1, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Paediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.
JNJ: 102.06 (+0.73)
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer
GlobeNewswire - Wed Dec 10, 12:41AM CST
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC(R), in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.
Bavarian Nordic Announces First Subject Dosed with MVA-BN(R) Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines
Thomson Reuters ONE - Thu Dec 04, 12:31AM CST
- First human trial investigating MVA-BN(R) Filo as an Ebola vaccine
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants
Thomson Reuters ONE - Tue Nov 18, 3:21AM CST
KVISTGAARD, Denmark, November 18, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 1,217,500 as a consequence of the exercise of warrants. After registration of the capital increase, Bavarian Nordic A/S' share capital amounts to DKK 275,665,970.
Bavarian Nordic Announces Interim Results for the First Nine Months of 2014
Thomson Reuters ONE - Thu Nov 13, 12:42AM CST
KVISTGAARD, Denmark, November 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2014.
Bavarian Nordic to Host Third Quarter 2014 Results Conference Call
Thomson Reuters ONE - Thu Nov 06, 10:30AM CST
KVISTGAARD, Denmark - November 6, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2014 third quarter results on Thursday, November 13, 2014.
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 29, 4:15AM CDT
Summary: Bavarian Nordic increases its share capital by nominally DKK 13,319,840 (1,331,984 new shares of DKK 10 each) as a result of a direct placement to Johnson & Johnson Development Corporation ("JJDC"
in connection with the license and supply agreement for the Company's MVA-BN(R) vector in respect of Ebola with Crucell Holland B.V., one of the Janssen Pharmaceutical companies of Johnson & Johnson. JNJ: 102.06 (+0.73)
Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN(R) for Additional Infectious Disease Targets
Thomson Reuters ONE - Wed Oct 22, 4:47PM CDT
KVISTGAARD, Denmark, October 22, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has agreed with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to expand the collaboration announced earlier today to include evaluation of Bavarian Nordic's proprietary vaccine platform technology, MVA-BN, for additional undisclosed disease targets.
JNJ: 102.06 (+0.73)
Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN(R) Ebola Vaccine
GlobeNewswire - Wed Oct 22, 1:06AM CDT
Bavarian Nordic A/S (OMX:BAVA) (OTC:BVNRY) announced today a global license and supply agreement for its MVA-BN Filovirus (Ebola and Marburg) vaccine candidate with Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
JNJ: 102.06 (+0.73)
Bavarian Nordic Announces Additional Details Concerning the Issue of Shares to Johnson & Johnson Development Corporation
Thomson Reuters ONE - Wed Oct 22, 12:56AM CDT
Summary: Further details on the placement of Bavarian Nordic shares to Johnson & Johnson Development Corporation ("J&J"
in connection with an agreement for co-development and commercialization of the Company's MVA-BN(R) vector in respect of Ebola. J&J will subscribe for Bavarian Nordic shares in the amount of DKK 251,000,000. However, Bavarian Nordic will issue a maximum of 1,673,333 shares of DKK 10 each (equal to approximately 6.4 per cent of the existing share capital of the Company). The number of subscribed shares may be lower than 1,673,333 shares depending on the final subscription price. The new shares will be subscribed for in cash at the market price which is based on the simple average of the volume weighted average price of the Company's shares on Nasdaq Copenhagen ("Nasdaq" (Bloomberg VWAP for BAVA.DC, referred to as "VWAP" during a period of five consecutive trading days starting on 22 October 2014, subject to a minimum subscription price of DKK 150 per share of DKK 10 corresponding to the closing price of the Company's shares on Nasdaq on 21 October 2014. JNJ: 102.06 (+0.73)
